Hyaluronic acid, MCLPE cross-linking chemistry, and the clinical rationale for Orvida's three product classes — written for licensed practitioners who need to understand what they are injecting.
Hyaluronic acid (HA) is a linear polysaccharide built from repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine. It occurs naturally throughout the body — highest concentrations sit in the dermis, synovial fluid, and vitreous humor — where it binds up to 1,000× its weight in water.
Native HA is cleared by hyaluronidase within 24–48 hours. For clinical use as a dermal filler, the molecule must be stabilised so it resists enzymatic degradation and retains volume for months, not hours. That stabilisation is called cross-linking.
Every Sofiderm formulation starts from bacterial-fermentation HA — non-animal source, ultra-high molecular weight, purified to medical-device grade. What differs between products is how the HA is stabilised, and whether it is stabilised at all.
MCLPE (Modified Cross-Linking Poly-Ether) is Sofiderm's proprietary process for stabilising HA chains using 1,4-butanediol diglycidyl ether (BDDE) as the cross-linker — the industry-standard chemistry also used by Juvéderm, Restylane, and Belotero.
What makes MCLPE specific is the degree of control over where BDDE attaches along the HA chain. Cross-linking only at unreacted hydroxyl sites produces a three-dimensional gel network that resists hyaluronidase cleavage while leaving enough free hydroxyl groups to maintain water-binding and tissue integration.
The result: biphasic gel cohesivity, predictable rheology, minimal residual BDDE (< 2 ppm, well below EU safety thresholds), and consistent batch-to-batch performance. Every lot is tested for viscoelastic modulus (G′), complex viscosity, and residual cross-linker.
Orvida's 23 SKUs fall into three chemistry-defined classes. Choosing correctly matters — cross-linking level, injection depth, and active complement are not interchangeable.
Structural dermal fillers. Cross-linked HA engineered for lift, volume, and predictable tissue integration across mid-to-deep dermal planes.
Hydration and bio-stimulation. Free HA chains delivered with active complexes for skin quality, hydration, and structural renewal — not volumisation.
Targeted mesotherapy. Active-ingredient formulations without HA-as-primary — delivered for specific indications (depigmentation, lipolysis, rejuvenation).
Rheology is not interchangeable. Each product class injects at a specific tissue plane.
Sofiderm products carry five accreditations. Not marketing labels — regulatory evidence.
Notified Body conformity assessment under EU Medical Device Regulation. Every batch legally placed on the EU market.
Medical-device quality management. Risk management, design controls, traceability, and pharmacovigilance baseline.
Single audit covering Australia, Brazil, Canada, Japan, and the USA. Five regulatory jurisdictions confirm the QMS.
Adverse-event reporting line active. Batch, lot, and expiry trace every vial back to manufacturing documentation.
The questions we hear most from clinicians evaluating Sofiderm for their clinic.
Yes. BDDE (1,4-butanediol diglycidyl ether) has been the HA cross-linker used in CE-marked fillers for over two decades — Juvéderm, Restylane, Belotero, Teosyal, and Sofiderm all use it. In the final gel product, residual unreacted BDDE is measured in parts per million and sits well below EU safety thresholds (typically < 2 ppm).
The cross-linker reacts with hydroxyl groups on the HA chain and becomes part of the polymer backbone; free BDDE is removed during dialysis and lot testing. Every Sofiderm batch includes residual-BDDE documentation.
All five are cross-linked HA at 20 ± 3 mg/ml — the difference is rheology: particle size, gel elasticity (G′), and cohesivity. Larger particles and higher G′ sit deeper and lift more.
Rough guide: Finelines — fine lines, peri-oral. Derm — nasolabial, mid-face. Deep — nose, chin, lip volume. Derm Plus — cheekbone, jawline. Derm Sub-Skin — deep structural support, malar. Full rheology specs on each product page, including G′ and particle size.
Because the goal is not volumisation — it's bio-stimulation. Non-crosslinked HA is cleared within days, delivering hydration and signalling to fibroblasts without occupying tissue space. Paired with peptides, vitamins, or polynucleotides, Revitalize products drive collagen turnover and skin quality without lift.
If you cross-linked a Revitalize formulation, you would change its mechanism. Different products, different goals.
Yes. Each manufactured lot is tested at Hangzhou Techderm for viscoelastic modulus (G′ and G″), complex viscosity, particle size distribution, residual BDDE (< 2 ppm target), HA concentration, pH, osmolarity, and sterility. Certificates of Analysis accompany shipments on request.
Sofiderm products are stable at 2–25°C. They are not frozen-chain. Our warehouse operates within that range and we use insulated shippers for cross-Iberia delivery. Products exposed above 25°C for extended periods should not be injected — temperature indicators accompany sensitive shipments.
Every Orvida verified clinical account has a direct line to our clinical-support team. Adverse events are reported to the clinical line, logged under our ISO 13485 pharmacovigilance system, escalated to the manufacturer's vigilance team at Hangzhou Techderm, and — where required — reported to the relevant competent authority (Infarmed in Portugal, AEMPS in Spain) within EU MDR timelines.
Reach adverse events team: info@orvida.eu or +351 966 261 224.
Verified clinical accounts receive full technical dossiers: batch CoAs, rheology curves, indication-by-depth guidance, clinical bibliography, and adverse-event protocols.